Veeral Ajmera is a Gastroenterology physician affiliated with University of San Diego. OpenAlex indexes 149 publications with 5,359 citations (h-index 39).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4168 Front St Fl 2
San Diego, CA 921032030
Telephone
619-543-5415Registry record last updated 9 Oct 2017.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Madrigal PharmaceuticalsProgram year202516 payments$30,607openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20251 payment
- Madrigal PharmaceuticalsProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.9%Bile Acid40.3%Ursodiol100%Part D<11 patientsProton pump inhibitor22.6%Omeprazole100%Part D<11 patientsCancer & immunology
37.1%Calcineurin inhibitor19.4%Tacrolimus100%Part D<11 patientsKinase inhibitor17.7%Everolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2023 per NIH RePORTER. The latest:
- A Novel Multimodal Approach to Characterize NAFLD Severity and Prognosis
University of California, San Diego
FY2023$204,552K23DK119460 - A Novel Multimodal Approach to Characterize NAFLD Severity and Prognosis
University of California, San Diego
FY2023$102,276K23DK119460 - A Novel Multimodal Approach to Characterize NAFLD Severity and Prognosis
University of California, San Diego
FY2022$204,552K23DK119460
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of <scp>MetALD</scp> Versus <scp>MASLD</scp>: A Prospective Study
Alimentary Pharmacology & Therapeutics
2025 - High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Journal of Hepatology
2025 - Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis
Clinical Gastroenterology and Hepatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Victor Nizet, MD
University of San Diego
Christopher Kane, MD
University of San Diego
Lawrence Marshall, MD
University of San Diego
Lyudmila Bazhenova, MD
University of San Diego
Charles Rice, MD
The Rockefeller University
Kris Kowdley, MD
Washington State University
Eamonn Quigley, MD
Houston Methodist Hospital and Academic Institute
Patrick Kamath, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”